BDX logo

BDX

Becton Dickinson and Company

$143.98
+$2.37(+1.67%)
64
Overall
95
Value
40
Tech
57
Quality
How is this score calculated?
Market Cap
$53.26B
Volume
6.23M
52W Range
$141.82 - $213.08
Target Price
$175.75

Company Overview

Mkt Cap$53.26BPrice$143.98
Volume6.23MChange+1.67%
P/E Ratio31.7Open$142.02
Revenue$21.8BPrev Close$141.61
Net Income$1.7B52W Range$141.82 - $213.08
Div Yield4.20%Target$175.75
Overall64Value95
Quality57Technical40

No chart data available

About Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector: Healthcare
Industry: Medical Instruments & Supplies

Latest News

BCAL launches blood test to monitor breast cancer recurrence

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has unveiled BREASTEST Monitor, a new blood test designed to evalu...

TipRanks Australian Auto-Generated Newsdesk2 days ago

The Week That Was, The Week Ahead: Macro and Markets, June 7

Ran Melamed13 days ago

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)

Catie Powers22 days ago

BD Resumes ChloraPrep Shipments Amid Ongoing FDA Review

TipRanks Auto-Generated Newsdesk22 days ago

BCAL Moves Toward U.S. Entry With Sonic Healthcare Validation Deal

TipRanks Australian Auto-Generated Newsdesk23 days ago
ABCD
1SymbolPriceChangeVol
2BDX$143.98+1.7%6.23M
3
4
5
6

Get Becton Dickinson and Company Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.